当前位置: X-MOL 学术Expert Rev. Vaccines › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?
Expert Review of Vaccines ( IF 5.5 ) Pub Date : 2021-04-28 , DOI: 10.1080/14760584.2021.1899817
Luis M de la Maza 1 , Toni L Darville 2 , Sukumar Pal 1
Affiliation  

ABSTRACT

Introduction

Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the world. Antibiotic treatment does not prevent against reinfection and a vaccine is not yet available.

Areas covered

We focus the review on the progress made of our understanding of the immunological responses required for a vaccine to elicit protection, and on the antigens, adjuvants, routes of immunization and delivery systems that have been tested in animal models. PubMed and Google Scholar were used to search publication on these topics for the last 5 years and recent Reviews were examined.

Expert opinion

The first Phase 1 clinical trial of a C. trachomatis vaccine to protect against genital infections was successfully completed. We expect that, in the next five years, additional vaccine clinical trials will be implemented.



中文翻译:

用于生殖器感染的沙眼衣原体疫苗:我们在哪里,还有多远?

摘要

介绍

沙眼衣原体是世界上最常见的性传播细菌病原体。抗生素治疗并不能预防再感染,而且还没有疫苗可用。

涵盖的领域

我们重点回顾我们对疫苗引发保护所需的免疫反应的理解所取得的进展,以及已在动物模型中测试的抗原、佐剂、免疫途径和递送系统。过去 5 年,PubMed 和 Google Scholar 用于搜索这些主题的出版物,并检查了最近的评论。

专家意见

沙眼衣原体疫苗预防生殖器感染的第一个 1 期临床试验已成功完成。我们预计,在未来五年内,将实施更多的疫苗临床试验。

更新日期:2021-07-06
down
wechat
bug